The 9-valent vaccine is not very useful for this population because women over 26 years of age are very likely to already have a history of infection from viral exposure, so women over 26 years of age cannot get the 9-valent. The 9-valent HPV vaccine is effective in preventing more than 90% of cervical cancers, especially for cervical cancers caused by human papillomavirus infection, and usually needs to be given through 3 injections over a period of about 6 months to be effective. The 9-valent HPV vaccine is mainly applicable to women between the ages of 16-26 years old, and has a strong protective effect against cervical cancer in this age range. It is recommended that women between the ages of 16 and 26 receive the HPV vaccine in a timely manner in order to minimize the occurrence of cervical cancer and prevent it from affecting their daily lives.